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Clustering of risk factors in hypertensive insulin-dependent diabetics
with high sodium-lithium countertransport. Diabetic nephropathy is
more common in patients with a positive family history of hypertension
and with elevated red blood cell sodium-lithium countertransport, a
marker of risk for essential hypertension. To evaluate whether there is
a relationship between this cation transport system and indicators of
risk of renal and cardiovascular complications in diabetic patients
before the development of clinical proteinuria, we studied 31 type I
(insulin-dependent) diabetic patients with arterial hypertension, without
clinical proteinuria and 12 normotensive normoalbuminuric diabetic
patients. Sodium-lithium countertransport activity was significantly
higher in hypertensive patients (0.43 0.03 mmol/I RBC x hr) than in
normotensive patients (0.23 0.03; P < 0.001). To better explore the
nature of the association between this transport system and arterial
hypertension, hypertensive patients were divided in two groups, with
high (>0.41 mmol/l RBC x hr) or normal (<0.41) sodium-lithium
countertransport activity. The two groups of hypertensive diabetics
were similar in age, sex, body mass index and blood pressure levels.
Hypertensive patients with elevated rates of sodium-lithium counter-
transport compared with those with normal sodium-lithium counter-
transport activity showed elevated glomerular filtration rate (130 4
ml/min/l.73 m2 vs. 122 3; P < 0.05), albumin excretion rate (median
26 gImin vs. II; P < 0.001), higher fractional proximal sodium
reabsorption (74 1.2% vs. 71.6 0.9; P < 0.01), exchangeable
sodium pool (2937 62 mmol/1.73 m2 vs. 2767 56; P < 0.01), larger
kidney volume (317 7 ml/l.73 m2 vs. 270 8; P < 0.05) and left
ventricular mass index (122 4 g/m vs. 107 5; P < 0.05).
Hypertensive patients with normal sodium-lithium countertransport
activity had renal parameters similar to normotensive diabetic patients,
except higher left ventricular mass index and kidney volume. Hyper-
tensive diabetic patients with elevated sodium-lithium countertransport
activity also had higher levels of plasma triglycerides, lower plasma
HDL-cholesterol and impaired insulin sensitivity (assessed by euglyce-
mic insulin-glucose clamp) compared with the other two groups. In
conclusion, renal, cardiac and metabolic abnormalities are prominent in
hypertensive type 1 (insulin-dependent) diabetic patients with higher
sodium-lithium countertransport.
Blood pressure rises early in the course of the renal disease of
insulin-dependent diabetes mellitus [1, 2] and diabetic nephrop-
athy is more common in patients with a positive family history
of hypertension [3, 4]. Moreover, elevated rates of red blood
cell sodium-lithium countertransport (Na/Li1 CT), a transport
system associated with the risk for essential hypertension [5—7],
have been found in diabetic patients who developed nephrop-
athy [4, 8], in patients with microalbuminuria [4, 9] and with
raised glomerular filtration rate [10] (2 precursors of overt renal
disease).
In hypertensive patients, though Na/Li CT is on average
elevated, there is considerable overlap with values in normoten-
sive subjects with approximately 50% of hypertensives showing
normal Na/Li CT activity [6]. Population studies have con-
firmed the association between Na/Li CT activity and hyper-
tension and have provided evidence for a major locus inheri-
tance, but this association is not complete, and it has been
suggested that the locus for Na/Li CT is a susceptibility
rather than a disease gene for hypertension [11].
Some authors have reported closer associations between
raised Na/Li CT activity and family history of hypertension
and cardiovascular disease than between Na/Li CT overac-
tivity and hypertension itself [6, 12, 13]. All these findings raise
the question as to whether an elevation of Na/Li CT char-
acterizes a particular subset of hypertensive patients prone to
target organ complications.
In the context of diabetes and hypertension, it becomes
important to discover whether there is a relationship between
the rates of Na/Li CT and indicators of risk of renal and the
attendant cardiovascular complications in diabetic patients
prior to the development of persistent proteinuria. This may
permit early identification of patients at risk of end organ
complications.
We therefore studied, in nonproteinuric, hypertensive insu-
lin-dependent diabetic patients, the rates of NatLi CT and
related them to indexes of renal and cardiovascular risk such as
albumin excretion rate, lipids, and renal functions, kidney and
heart size and insulin resistance.
Methods
Patients
© 1992 by the International Society of Nephrology
Thirty-one insulin-dependent diabetic patients with elevated
arterial pressure, but otherwise free of any other clinically overt
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complication, attending the outpatient diabetic clinics of the
Department of Internal Medicine, University of Padova and
two District General Hospitals in the Veneto region (Pordenone
and Monfalcone) were recruited for this study on the basis of
three selection criteria: 1) blood pressure levels higher than 140
mm Hg for systolic and 90 mm Hg for diastolic value in absence
of anti-hypertensive treatment; 2) urine negative for albustix
test (Boehringer-Manheim, Germany); and 3) duration of dia-
betes lower than 11 years. The patients were otherwise free of
any other clinically overt complication.
A matched group of twelve normotensive diabetic patients
recruited from the same clinics served as controls. Physical
activity (moderate noncompetitive exercise 4 to 5 hours per
week) was similar in all subjects, as well as were smoking habits
and alcohol intake. All subjects were Caucasian with normal
serum creatinine concentration. Blood pressure (diastolic phase
V) was measured in the sitting position after 10 minutes of rest
to the nearest 2 mm Hg using a random zero sphygmomanom-
eter. Causes of secondary hypertension were excluded by a
complete medical work up with a 12 lead ECG. All subjects had
normal renal, liver and endocrine function and were following
an isocaloric diet containing 50% carbohydrate, 25% fat and
25% protein and about 100 mmollday sodium chloride. Timed
overnight urine collections for urinary albumin measurement
[14] were performed at least four times over a period not
exceeding six months. Patients were admitted to a metabolic
ward a week prior to the study and all anti-hypertensive
medications were discontinued for at least a week prior to
admission.
In the six months preceding admission all patients were
changed to three insulin injections a day and followed at least
once a month in order to stabilize their metabolic control.
Glycosilated hemoglobin A1 (HbA1) records of their meta-
bolic control were available from case notes over the preceding
three years. Daily insulin requirement was measured for 30
days after the first visit and the 30 days preceding the study.
The average of the insulin requirements during the two monthly
periods was then used.
A fasting blood sample was taken in a heparin-treated syringe
for measurement of Na/Li CT, as previously described by
Canessa et al [5], at different times from ten to six months
before each study. Studies were carried out during the last two
to three days of admission in the hypertensive patients and on
an outpatient basis in the normotensive diabetic controls. The
day before renal function determination, the patients omitted
any intermediate-acting insulin injection and received short-
acting insulin doses only at 8:00 a.m. and at 12:00 a.m. At 6:00
p.m., a constant subcutaneous infusion of insulin (Actarapid
Human, Novo, Rome, Italy) at a rate of 15 mU/kg/hr with a
bolus MC2O insulin-infusion device (Miles, Ames, Cavenago,
Mi, Italy) was started to achieve and maintain euglycemia. In
the evening, all patients were given 16.2 mmol of lithium
carbonate orally. Food, alcohol, coffee, tea and smoking were
prohibited after 10:00 p.m. In the morning, the overnight
constant insulin infusion was continued and the patients con-
nected to an artificial pancreas (Biostator, Miles-Ames) run in
mode 9:1 to maintain blood glucose at 4.7 mmol/liter with the
infusion of glucose [15, 161. All experiments were performed
under comparable conditions of fluid infusion. At 7:00 a.m., a
wrist vein was cannulated in a retrograde manner and the hand
placed in a warming box to arterialize venous blood for blood
sampling to measure hormone and metabolite levels and Na/
Li CT for a second time. Subjects drank 1 liter of tap water
followed by 0.3 liter of water every 30 minutes throughout the
study to induce a steady state of water diuresis at 8 to 10
ml/min. At 8:00 a.m., an indwelling catheter was placed in an
antecubital vein of the opposite arm, and priming doses of 50
tCi 51Cr-EDTA followed by constant infusion of 0.7 Ci/min of
the tracer was given to determine GFR as previously indicated
[15, 16]. Patients remained supine throughout the experiment,
standing only to void. After two hours of tracer equilibration,
urine was collected for four thirty minute periods. Blood was
drawn at the midpoint of each urine collection. Lithium clear-
ance and sodium excretion rate were measured simultaneously
[15, 16]. For total exchangeable sodium, a dose of 60 iCi of
24Na was given orally after an overnight fast and urine was
collected during the subsequent 24 hours. During the last hour,
four blood samples were obtained for determination of sodium
specific activity [17]. On a separate day, insulin sensitivity was
assessed by the use of an euglycaemic insulin-clamp technique
previously reported [18, 191. Briefly, a constant infusion of
insulin (Actrapid HM, Novo, Denmark) was given at a rate of
30 mU/hr/kg for 180 minutes followed by a rate of 90 mU/hr/kg
for the next 180 minutes. Plasma glucose concentration was
maintained constant by a variable infusion of exogenous glu-
cose (20% wt/vol). The amount of glucose required to main-
tained euglycemia equals whole body glucose disposal, when
endogenous glucose production is added to this value. Endog-
enous glucose production was determined by isotope dilution
technique using 6,6-2H2 glucose (98.6% 2H2; Merk Isotopes,
Montreal, Canada). This tracer was administered as a primed (2
mg/kg) constant (0.019 mg/kg/mm) infusion for two hours before
the start of the insulin-clamp period and was continued through-
out the experimental period.
Analytical measurements and data analysis
Plasma glucose was assayed by the glucose oxidase method
(Beckman Glucose Analyzer, Beckman Instruments, Fullerton,
California, USA). Hemoglobin A1 was determined by micro-
column chromatography (Bio Rad Laboratories, Richmond,
California, USA). Plasma free insulin was measured by radio-
immunoassay technique [20].
Lithium (Li) was determined in diluted samples by flame
photometry for lithium clearance determination [16] and by
atomic emission spectrophotometry for Na/Li CT activity
determination [5]. Sodium in urine and plasma was determined
by flame photometry. Li clearance was calculated according
to standard formulas.
Rates of glucose turnover were calculated from the isotopic
data using a two-compartment model for non-steady-state glu-
cose kinetic [21, 22]. Proximal sodium reabsorption (PRNa)was
calculated as follows:
PRNa = PNNa x GFR x FRLI
where 'Na is plasma sodium and FRLI = 1 — (V/GFR) x (U1J
PL) where ULI/PLI is the urine to plasma ratio of lithium and V
the urine flow.
Kidney and cardiac volumes were measured by an ultrasound
technique [23, 241. The volume of both kidneys was measured
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and the mean of the two values used for calculations. Each
subject was submitted to a 2-D derived/M-mode echocardio-
graphic study with a mechanical 2.5 MHz probe and a commer-
cially available instrumentation (Esacord 81, OTE Biomedica,
Italy). According to the American Society of Echocardiography
[24], the following parameters relative to left ventricle were
obtained, each as an average of at least three measurements:
—left ventricular end-diastolic dimension (LVDd)
—left ventricular end-systolic dimension (LVSd)
—left ventricular diastolic posterior wall thickness (LVPW)
—interventricular septum thickness (IVS)
From these measurements left ventricular mass index (LVMI)
was calculated according to the Devereux formula [25].
Total exchangeable sodium was measured by radioisotope
dilution technique using 24Na [17].
Fasting serum was separated and stored at 4°C for determi-
nation of lipids within five days. High density lipoproteins
(HDL) were separated by ultracentrifugation [26]. Concentra-
tions of cholesterol [27] and triglycerides [28] were measured by
enzymatic colorimetric techniques.
The results are expressed as mean SEM. Analysis of
variance was used for statistical evaluation of differences
among groups. If a significant difference was found, differences
between individual groups were tested by unpaired Student's
r-test (unless otherwise stated) and data were subjected to
Bonferroni correction for multiple comparisons. Correlation
between variables was assessed by Spearman-Rank analysis.
Results
Sodium-lithium countertransport (Na/Li CT) activity in
the 31 hypertensive IDDM patients was significantly higher
than that of the 12 normotensive IDDM control patients, but
there was a large overlap between the two groups (Fig. 1). After
six months of strict metabolic control, HbAC value decreased
from 7.2 0.4 to 6.2 0.4 (P < 0,01) in normotensive and from
8.1 0.3 to 6.2 0.3 (P < 0.01) in hypertensive IDDM
patients. Insulin daily requirement increased from 0.62 0.08
U/kg/day to 0.75 0.07 (P < 0.05) in normotensive and from
0.71 0.05 to 0.93 0.05 (P < 0.01) in hypertensive IDDM
patients. Daily insulin requirement after six months of strict
metabolic control was significantly higher in hypertensive (P <
0.01) than in normotensive diabetic patients. No significant
change was found with regard to Na/Li CT activity (nor-
motensives from 0.23 0.04 to 0.23 0.03 mmol/liter RBC/hr;
hypertensives from 0.42 0.02 to 0.43 0.03).
The wide range of Na/Li CT values in hypertensive
patients suggests heterogeneity among the hypertensive dia-
betic patients. To further explore this phenomenon we there-
fore compared a number of variables in hypertensive patients
with supranormal Na/Li CT with those of hypertensive
patients with their countertransport activity within the normal
range. In our laboratory the normal range of Na/Li CT in 35
normal subjects without family history of hypertension ranged
from 0.11 to 0.41 mmol/liter RBC/hr. Fourteen of the hyperten-
sive diabetic patients had Na/Li CT activity greater than the
upper limit of normal range (Group H2D; mean SEM; 0.55
0.03) while seventeen had Na/Li CT within the normal range
(Group H1D: 0.31 0.02; P < 0.01). All twelve normotensive
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Table 1. Clinical data of 31 hypertensive type 1 (insulin-dependent)
diabetic patients with high (H2D) and normal (H1D) Na/Li CT
activity and of 12 normotensive type I (insulin-dependent) diabetic
patients (ND)
H2D H1D ND
Sex (M/F) 9/5 11/6 7/5
Age years 27 2 29 2 31 2
Duration of diabetes years 9 1 8 1 7 I
Body mass index kg/rn2 22.7 0.6 22.7 0.3 22.5 0.5
Systolic blood pressure mm Hg 164 5 156 4 125 2
Diastolic blood pressure mm Hg 102 2 99 3 80 I
Duration of antihypertensive 1.9 0.4 2.1 0.3 —
treatment years
diabetic patients had Na/Li CT activity within the normal
range (Group ND).
The three groups of insulin-dependent diabetic patients were
comparable for age, sex distribution, body mass index and
duration of diabetes. The two groups of hypertensive diabetic
patients had similar levels of blood pressure and duration of
antihypertensive treatment (Table 1). When patients were re-
cruited, they were taking the following drugs: ACE inhibitors (6
patients in Group H2D vs. 5 in HID), furosemide (2 in H2D vs.
2 in H1D), nifedipine (7 in H2D vs. 9 in H1D), and thiazides (I
in H2D vs. 3 in H1D).
No difference were found in total cholesterol (4.81 0.13
mmol/liter in H2D; 4.73 0.14 in H1D and 4.91 0.19 in ND)
plasma levels. The cholesterol fraction in high density lipopro-
teins (HDL cholesterol) was significantly lower in H2D (1.10
1.00—
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Fig. 1. Sodium-lithium countertransporr (Na7Li CT) activity in red
blood cells of twelve normotensive insulin-dependent diabetics (ND)
and thirty-one hypertensive insulin-dependent diabetics (HD). The
broken line indicates the upper limit of normals (see text).
Values are given as mean so.
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Table 2. GFR, albumin excretion rate (AER), fractional proximal
sodium reabsorption (FPNaR), sodium pool, mean kidney volume
and left ventricular mass index (LVMI) of hypertensive diabetic
patients with high (H2D) and normal (H1D) Na/LiCT activity and
of normotensive diabetic patients (ND)
H2D H1D ND
GFR mi/min/I.72 m2 130 4 122 3 117 2
AER pg/min
FPNaR %
26 (9)b.C
75.4 1.2'
11(5—23)
71.6 0.9
6 (3—13)
72.5 0.5
Sodium pool 2937 62ie 2767 56 2782 104
mmol/l.72 ,n2
Mean kidney volume
mi/i .73 m2
313 7C 270 8' 228 18
LVMI g/m2 122 4 107 5d 91 2
Values are given as mean SD except for AER which is given as
median (range).
ap < o•5, b p < 0.01 H2D vs. H,D
c p < 0.01 H2D vs. NDd P < 0.05 H1D vs. ND
0.03 mmol/liter) than in H1D (1.6 0.09; P < 0.05) and in ND
patients (1.9 0.08; P < 0.01). Plasma triglycerides were also
significantly higher in H2D compared with the other two groups
of patients (1.62 0.10 mmol/liter in H2D; 1.53 0.11 in H1D;
P < 0.05; and 1.39 0.07 in ND; P < 0.01),
Plasma sodium concentrations were similar in the three
groups (H2D vs. H1D vs. ND 141 3 vs. 140 2 vs. 139 2
mmol/liter) as well as sodium excretion rate (216 8 vs. 224
10 vs. 198 11 mmol/24 hr), but fractional proximal tubule
sodium reabsorption rate was significantly higher in H2D than in
H1D (P < 0.01) and in ND patients (P <0.01; Table 2).
Sodium pooi was significantly greater in H2D patients than
both H1D (P < 0.01) and ND patients (P < 0.01) who showed
similar values. Albumin excretion rate was significantly ele-
vated in H2D patients compared to H1D and ND patients. All
ND patients had albumin excretion rates lower than 20 /Lglmin
(normal range in our laboratory: 1 to 20 gImin) while 2 out of
the 17 H1D and 7 out of 14 H2D patients showed an albumin
excretion rate in the microalbuminuric range. The glomerular
filtration rate was higher in H2D than in H1D (P < 0.05) and in
ND patients (P < 0.01). Both H1D and H2D groups showed
higher LVMI and mean kidney volume than ND patients, but
they were significantly greater in H2D patients than in H1D
group (Table 2).
In the fasting postabsorptive state plasma glucose concentra-
tion was similar in all groups (H2D vs. H1D vs. ND: 81 3
mg/dl vs. 80 2 vs. 79 2) as well as plasma insulin
concentration (21 2 rU/ml vs. 22 3 vs. 22 3).
During glucose clamp (Fig. 2) plasma insulin levels rose to a
similar plateau in the three groups during the first (H2D 45 3
jU/ml; H1D 46 3; ND 47 4) and second insulin infusion
period (H2D 101 7; H1D 103 4; ND 107 8). Plasma
glucose levels were maintained at around 85 mg/dl throughout
the study in all three groups. The amount of exogenous glucose
required to hold glucose level constant was significantly smaller
in H2D patients (14.2 2.1 and 40.1 1.9 g/160 minll.73 m2)
than in H1D patients (18.8 2.3 and 55.4 5.2; P < 0.05) and
in ND subjects (20.8 2.3 and 62.4 4.8; P < 0.01) during the
low and high insulin clamp, respectively.
Whole body glucose utilization, calculated using [6.6 2H2]
glucose dilution data, was significantly lower in H2D patients
during the first and second insulin plateau than in H1D and ND
patients (first plateau, 2.23 0.24 mg/kg/mm vs. 3.17 0.26 vs.
3.39 0.31, P < 0.01 for both, respectively; second plateau:
3.88 0.34 mg/kg/mm vs. 5.41 0.39 vs. 5.88 0.41, P < 0.01
for both).
Endogenous glucose production rate at baseline was similar
in the three groups and averaged 2.29 0.19 mg/kg/mm in ND
patients, 2.19 0.22 in H1D patients, and 2.27 0.31 in H2D
patients. Insulin infusion promptly and similarly inhibited
endogenous glucose release by about 50% during the first
insulin plateau and by about 100% during the second insulin
plateau in all groups (Fig. 2).
Discussion
The combination of diabetes mellitus and hypertension has a
devastating effect on the kidney, the heart and the arteries [29,
30]. The insulin-dependent diabetic patients who have devel-
oped proteinuria and are prone to cardiovascular complications
have been recently found to have higher rates of sodium-lithium
countertransport [4, 8] and to belong to families with a higher
frequency of parental arterial hypertension [3, 4]. The present
study demonstrates that elevated rates of sodium-lithium coun-
tertransport identifies a subgroup of as yet uncomplicated
hypertensive insulin-dependent diabetic patients in whom a
striking aggregation of early risk indicators for renal and car-
diovascular complications occurs. Hypertensive insulin-depen-
dent diabetic patients with raised sodium-lithium countertrans-
port activity showed higher albumin excretion rate, greater
renal sodium reabsorption and total body exchangeable sodium
pool, enlarged kidneys and hearts, worse glycemic control and
a reduced insulin sensitivity. All of these parameters have been
related with the later development of renal and cardiovascular
complications in the general as well as in the diabetic popula-
tion.
Our findings are consistent with the observation that only a
subset of hypertensive or diabetic subjects are at risk of end
organ complications. This risk appears to be related to the
possession of an abnormal sodium-lithium countertransport
activity. Other workers have suggested the possible association
of elevated rates of sodium-lithium countertransport with car-
diovascular complications in non-diabetic patients with hyper-
tension or renal disease [10, 11, 31].
Microalbuminuric insulin-dependent diabetic patients have
been reported to have higher rates of sodium-lithium counter-
transport [9]. In spite of similar levels of elevated blood
pressure only 12% of the hypertensive patients with normal
countertransport had marginally elevated albumin excretion
rate. By contrast 50% of hypertensive patients with elevated
sodium-lithium countertransport were microalbuminuric. This
finding is in agreement with early reports in essentially hyper-
tensive patients which showed that microalbuminuria only
occurs in a subgroup of individuals [32, 33]. It suggests that
elevation of blood pressure per se may not be sufficient to alter
the albumin excretion rate and that other factors are at work.
Glomerular hyperfiltration has also been suggested to be a
predictor of subsequent renal damage [34, 35], and recently it
has been associated with an increased sodium-lithium counter-
transport activity [101. In our study the hypertensive diabetics
with high sodium-lithium eountertransport also showed an
increased GFR. It is of interest that these patients also had
0 60 120 180 240 300 360 420 480
Fig. 2. Mean SE for plasma glucose, free
insulin concentrations, and endogenous
glucose production in normotensive diabetic
(—LI—), in hypertensive diabetic patients with
high (—•——) and normal (—0—) Na/Li CT
activity at baseline and during stepwise
insulin-glucose clamp. The bars on the lower
panel indicate whole body glucose utilization
rates in normotensive diabetics (LI) and
hypertensive diabetics with normal (0) and
high () Na/Li CT. < 0.05 ** < 0.01
hypertensive diabetics with high Na/Li CT
vs. ND.
nephromegaly, an increased estimated proximal sodium reab-
sorption and sodium pooi, suggesting a more pronounced
sodium retention. The abnormalities in sodium metabolism we
have described resemble those reported in essential hyperten-
sive patients with non-modulating hypertension [361 who also
had higher sodium-lithium countertransport activity [371.
In our study hypertensive diabetics had echographic evi-
dence for cardiac hypertrophy. Our findings of more pro-
nounced left ventricular hypertrophy in patients with high
sodium-lithium countertransport are interesting in that the
presence of cardiac hypertrophy is well known to increase the
frequency of cardiovascular morbidity and mortality [38, 39].
That cardiac hypertrophy was not simply the consequence of
the mechanical effect of increased blood pressure but was more
closely associated to the presence of an overactivity of sodium-
lithium countertransport is supported by the observation that
blood pressure levels and duration of hypertension were similar
in the two groups of hypertensive diabetic patients.
The current study also demonstrates that a greater insulin
resistance is a further clinical feature of these hypertensive
insulin-dependent diabetic patients with high sodium-lithium
countertransport. These patients also had a worse metabolic
control in the years preceding the study (as testified by HbAIC
value) and the greater daily insulin dose required to achieve a
strict metabolic control in the period immediately preceding the
euglycemic clamp study. The site of impaired insulin action was
the peripheral tissues and not the liver. In fact, endogenous
glucose production was similar in all diabetic patients, indepen-
dently of blood pressure levels, and was similarly inhibited by
both moderate and high plasma insulin levels. Both diabetes
and essential hypertension have been reported to be a state of
insulin resistance [40, 41], a phenomenon proposed to be an
independent risk factor for coronary artery disease [42]. How-
ever, only a proportion of hypertensive patients develops
cardiovascular and renal complications [43], and only a subset
of insulin-dependent diabetic patients develops similarly late
organ damages [44]. That insulin resistance in type 1 (insulin-
dependent) diabetes is influenced by a great number of variables
(duration of disease, previous metabolic control, body mass
index, sex, age) is well known [45], but, to date, no studies have
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been addressed to the relationship between insulin resistance,
arterial hypertension and sodium-lithium countertransport in
insulin-dependent diabetic patients. Of particular interest is that
both insulin resistance and high sodium-lithium countertrans-
port have been found to be associated with lipid abnormalities
[9, 46, 47]. All these factors which are believed to be a risk for
cardiovascular disease seem therefore to cluster in the same
individuals.
The nature of the association between sodium-lithium coun-
tertransport activity and insulin resistance as well as the other
abnormalities we have described remain to be established.
Some evidence has been provided that sodium-lithium counter-
transport is a mode of operation of the ubiquitous physiological
sodium-hydrogen antiport [481, a cell membrane system in-
volved in the intracellular pH regulation, in the processes
leading to cell growth and replication and, at kidney level, in the
tubular reabsorption of sodium [491. Insulin stimulates the
sodium-hydrogen antiport in various cell types [49] and the
sodium-hydrogen antiport has been shown to be linked with
calcium exchange [50]. Increase in both intracellular sodium
and calcium are known not only to enhance the sensitivity of
smooth muscle cells to pressor factors [511, but also to stimulate
cell growth and proliferation [52]. This sequence of events
could result in the cardiac and renal hypertrophy observed in
our hypertensive diabetic patients with high sodium-lithium
countertransport activity. Consistent with this, it is possible
that insulin resistance and therefore the consequent hyperinsu-
linemia could cause a further elevation of sodium-hydrogen
activity. That an overactivity of this system is associated with
impaired glucose metabolism is supported by recent experi-
ments in spontaneously hypertensive rats (SHR) in which the
lower insulin-induced glucose uptake by brush border mem-
brane vesicles was ascribed to an enhanced dissipation of
sodium gradient across brush border membrane, secondary to a
higher sodium-hydrogen antiport activity [53].
Whatever the relationship between insulin resistance and
abnormality in Na/Li CT activity, it is interesting that our
data show an association between higher levels of HbA1 and
the occurrence of microalbuminuria in insulin-dependent dia-
betic patients irrespective of the presence of hypertension (Note
added in proof). These findings are in keeping with those of
Krolewski et al [4] reporting a significant positive correlation
between blood glucose retrospective levels and albumin excre-
tion rate. Moreover, the same group [54] observed more re-
cently that insulin-dependent diabetic patients with elevated
Na/Li CT activity were to some extent protected against the
development of kidney damage by a good metabolic control,
despite the presence of this abnormality in cell cation transport
system. All together these data support the hypothesis that a
poor metabolic control can also alter kidney function in insulin-
dependent diabetic patients, particularly in that cohort of pa-
tients already characterized by an elevated Na/Li CT activ-
ity.
In conclusion, we have shown that a number of metabolic and
morphological abnormalities predictive of subsequent renal and
cardiovascular damage are clustering together in hypertensive
insulin-dependent diabetic patients with high sodium-lithium
countertransport activity. This finding clearly suggests that a
high sodium-lithium countertransport activity could be a
marker for those patients most at risk of renal and cardiovas-
cular complications.
Note added in proof
Similarly, we recently observed that impaired insulin sensitivity
characterizes only those patients with essential hypertension, who also
have high Na/Li CT activity (A) and cardiorenal abnormalities (B).
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